Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

IMM2510 Induces Early Efficacy in Advanced, Immunotherapy-Exposed Squamous NSCLC

September 12th 2025

The PD-L1– and VEGF-directed bispecific antibody IMM2510 proved active in patients with squamous NSCLC after prior chemotherapy and immunotherapy.

MRI and Ultrasound May Be Best Used in Tandem for Surveillance Imaging in Soft Tissue Sarcoma

September 12th 2025

Ultrasound is cheaper, faster, and is widely available compared with MRI, but is it enough to displace the gold standard imaging tool?

Bexobrutideg Shows Early Promise in BTK- and BCL2-Exposed, Relapsed/Refractory CLL

September 12th 2025

The novel BTK degrader led to fast-onset responses that were maintained over time in patients with CLL/SLL.

FDA Grants Fast Track Designation to GLSI-100 in HLA-A*02+, HER2+ Breast Cancer

September 10th 2025

GLSI-100 received fast track designation from the FDA for patients with HLA-A*02- and HER2-positive breast cancer after SOC therapy.

FDA Approves Selumetinib for Symptomatic Pediatric NF-1–Associated Inoperable Plexiform Neurofibromas

September 10th 2025

The FDA approved selumetinib granules and capsules for the treatment of pediatric patients at least 1 year of age with NF1 and plexiform neurofibromas.

Repotrectinib Demonstrates Durable Efficacy in TKI-Naive and -Pretreated ROS1+ NSCLC

September 10th 2025

Repotrectinib elicited durable responses, including intracranial responses, in TKI-naive and -pretreated patients with NSCLC.

Elenestinib May Be Safer Than Traditional KIT Inhibitors in Indolent Systemic Mastocytosis

September 10th 2025

Tsewang Tashi, MD, discusses how elenestinib could be an effective option with a manageable safety profile in ISM.

Dr Xia on the Differences Between ctDNA Monitoring Strategies in MET Exon 14–Mutant NSCLC

September 9th 2025

Yang Xia, MD, PhD, discusses the use of different ctDNA monitoring to detect resistance and predict outcomes in NSCLC with MET exon 14 skipping mutations.

Dr Lim on the Potential Role for Subcutaneous Amivantamab in EGFR-Mutant NSCLC

September 9th 2025

Sun-Min Lim, MD, PhD, discusses the potential adoption of first-line subcutaneous amivantamab plus chemotherapy in EGFR-mutant NSCLC.

Dr Patel on Remaining Gaps in Biomarker Testing for Early-Stage Resected NSCLC

September 8th 2025

Sandip P. Patel, MD, discusses remaining gaps in biomarker testing and their implications for targeted therapies in early-stage NSCLC.

Dr Singhi on Responsibly and Effectively Leveraging Social Media for Patient Education in Oncology

September 8th 2025

Eric K. Singhi, MD, expands on how oncologists can work with patient advocacy groups on social media to improve patient education and engagement.

Final Analysis of Perioperative Tislelizumab Plus Chemotherapy Shows Sustained OS and EFS Improvement in Resectable NSCLC

September 8th 2025

Perioperative tislelizumab plus chemotherapy showed sustained OS and EFS improvement vs chemotherapy in resectable NSCLC.

Zidesamtinib Data Align With Clinical Expectations in Pretreated ROS1+ Advanced NSCLC

September 7th 2025

The brain-penetrant, TRK-sparing, ROS1-selective TKI zidesamtinib was active and safe in patients with advanced ROS1+ non–small cell lung cancer.

Ivonescimab Plus Chemo After Third-Generation TKI Generates Improved PFS in EGFR-Mutated NSCLC

September 7th 2025

Ivonescimab plus chemotherapy showed significant and clinically meaningful PFS in EGFR-mutated NSCLC following progression on a third-generation TKI.

Dr Liu on Updated Efficacy and Safety Data With Taletrectinib in ROS1+ NSCLC

September 7th 2025

Geoffrey Liu, MSc, MD, discusses updated efficacy and safety results with taletrectinib in ROS1-positive non–small cell lung cancer.

Dr Drilon on the Efficacy of Zidesamtinib Relative to Other ROS1 Inhibitors in Pretreated ROS1+ NSCLC

September 7th 2025

Alexander Drilon, MD, compares response rates with zidesamtinib with that of prior ROS1 inhibitors in pretreated patients with ROS1-positive NSCLC.

Mosunetuzumab Plus Polatuzumab Vedotin Triples Median PFS in Transplant-Ineligible LBCL

September 6th 2025

A chemotherapy-free regimen of mosunetuzumab and polatuzumab vedotin improved PFS and response rates vs R-GemOx in relapsed/refractory LBCL.

Off-the-Shelf, Fixed-Duration Combination Is Active in Relapsed/Refractory MCL

September 6th 2025

Treatment with mosunetuzumab plus polatuzumab vedotin yielded high response rates and had a manageable safety profile in BTK inhibitor–exposed MCL.

Orca-T Improves Moderate to Severe cGVHD-Free Survival in Hematologic Malignancies

September 5th 2025

Treatment with an investigational allogeneic T-cell immunotherapy improved outcomes vs conventional transplant in patients with hematologic malignancies

Dr Tashi on Differentiating Characteristics of Elenestinib in Indolent Systemic Mastocytosis

September 5th 2025

Tsewang Tashi, MD, discusses the aspects of elenestinib that differentiate it from avapritinib in the management of indolent systemic mastocytosis.